Search Results - subject:"reference pricing"

Incentives and pharmaceutical reimbursement reforms in Spain

Puig, Jaume - Department of Economics and Business, Universitat … - 2003

products was introduced in 1998. Second, a reference pricing system was introduced in December 2000, with annual updating and …

Persistent link: https://www.econbiz.de/10005771934

Incentives and pharmaceutical reimbursement reforms in Spain

Puig, Jaume - Department of Economics and Business, Universitat … - 2003

products was introduced in 1998. Second, a reference pricing system was introduced in December 2000, with annual updating and …

Persistent link: https://www.econbiz.de/10005704975

The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume II: Technical Report

Grootendorst, Paul V.; Dolovich, Lisa R.; Holbrook, Anne M. - Department of Economics, McMaster University - 2002

(see SEDAP 70 for abstract)

Persistent link: https://www.econbiz.de/10005404416

The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume I: Summary

Grootendorst, Paul V.; Dolovich, Lisa R.; Holbrook, Anne M. - Department of Economics, McMaster University - 2002

Objective: We estimate the effects of Reference Pricing, a drug cost control policy introduced by the BC Ministry of … services. Rationale: Reference pricing (RP) limits the reimbursement of a group of drugs with similar therapeutic effect but …

Persistent link: https://www.econbiz.de/10005763258

The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume III: ACE and CCB Literature Review

Dolovich, Lisa R.; Holbrook, Anne M.; Woodruff, Margaret - Department of Economics, McMaster University - 2002

(see SEDAP 70 for abstract)

Persistent link: https://www.econbiz.de/10005763264

The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume III: ACE and CCB Literature Review

Dolovich, Lisa R.; Holbrook, Anne M.; Woodruff, Margaret - Department of Economics, McMaster University - 2002

(see QSEP 369 for abstract)

Persistent link: https://www.econbiz.de/10005181106

The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume I: Summary

Grootendorst, Paul V.; Dolovich, Lisa R.; Holbrook, Anne M. - Department of Economics, McMaster University - 2002

Persistent link: https://www.econbiz.de/10005181109

The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report

Grootendorst, Paul V.; Dolovich, Lisa R.; Holbrook, Anne M. - Department of Economics, McMaster University - 2002

(see QSEP 369 for abstract)

Persistent link: https://www.econbiz.de/10005181110

The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany

Stargardt, Tom - In: The European Journal of Health Economics 11 (2010) 3, pp. 267-277

Persistent link: https://www.econbiz.de/10008486763

Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark

Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas - Centre for Industrial Economics (CIE), Økonomisk Institut - 2010

On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements for pharmaceutical purchases, are calculated. The previous reference prices, which were based on average EU prices, were substituted to minimum domestic prices. Novel to the literature, we estimate...

Persistent link: https://www.econbiz.de/10008534454